Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01526746
Other study ID # VP-VEC-162-1106
Secondary ID
Status Completed
Phase Phase 1
First received January 26, 2012
Last updated February 14, 2014
Start date February 2012
Est. completion date June 2012

Study information

Verified date February 2014
Source Vanda Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals who have normal renal function. The safety and tolerability of tasimelteon will also be assessed throughout this study.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 79 Years
Eligibility Inclusion Criteria:

Groups 1-3

1. Ability and acceptance to provide written informed consent;

2. Men or women between 18 - 79 years, inclusive;

3. Subjects with Body Mass Index (BMI) of >18 and <40 kg/m2 (BMI = weight (kg)/ [height (m)]2);

4. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control for a period of 35 days before the first dosing and have a negative pregnancy test at the screening and baseline visits; Note 1: Acceptable methods of birth control include any one of the following: abstinence, vasectomized sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam.

5. Willing and able to comply with study requirements and restrictions;

Groups 1- 2 (renal impairment)

1. Subjects with renal impairment defined as

1. Group 1: Stage 5 End Stage Renal Disease (ESRD) (eGFR < 15 mL/min/m2) requiring regularly scheduled dialysis and have been on a stable dialysis regimen for at least three months at baseline; OR

2. Group 2: Stage 4 severe renal impairment (eGFR = 29 mL/min/m2) but not requiring dialysis as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (Appendix 18.3)

2. Otherwise considered healthy in general as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening;

3. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below.

1. Body temperature between 35.0-37.5 °C;

2. Systolic blood pressure between 100-180 mmHg;

3. Diastolic blood pressure between 60-115 mmHg;

4. Pulse rate between 40-100 bpm.

Group 3 (healthy matched controls)

1. Subjects in Group 3 must match in gender, smoking status, age (±10 years), and body mass index [normal BMIs (18.00-24.99), overweight BMIs (25.00-30.99) and obese BMIs (31.00-40.00)] to Group 1 and/or 2;

2. Subjects must have normal renal function defined as eGFR = 80 mL/min/m2 as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (Appendix 18.3 );

3. Subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis;

4. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:

1. Body temperature between 35.0 - 37.5 °C;

2. Systolic blood pressure between 90 - 150 mmHg;

3. Diastolic blood pressure between 50 - 95 mmHg;

4. Pulse rate between 40 - 90 bpm.

Exclusion Criteria:

Groups 1-3

1. Smokers (use of tobacco products in the previous 3 months) unable or unwilling to limit consumption to 10 cigarettes per day or less while checked into the inpatient facility.

a. Note: Smoking will be a match criteria and the site should attempt to enroll an equal number of smokers and non-smokers into each group.

2. Exposure to any investigation drug, including placebo, within 30 days or 5 half-lives (whichever is longer) of dosing;

3. Donation or loss of 400 mL or more of blood within two months prior to dosing;

4. Significant illness within the two weeks prior to dosing;

5. Answer 'yes' to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the "Suicidal Ideation" portion of the C-SSRS, or answer "yes" to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior) on the "Suicidal Behavior" portion of the Columbia Suicide Severity Rating Scale (C-SSRS); and the ideation or behavior occurred within the past 6 months;

6. Functioning renal transplant;

7. History within the past 2 years of clinically significant acute or chronic bronchospastic disease, including asthma and chronic obstructive pulmonary disease, treated or not treated;

8. Treatment with any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 day preceding the Screening visit;

9. Participation in a previous BMS-214778/VEC-162 trial;

10. History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening or evidence of such abuse as indicated by the laboratory assays conducted during the screening and baseline visits. A positive drug screen in Groups 1 and 2 is acceptable if there is documentation that subjects have been prescribed the corresponding medication;

11. History of immunocompromise, including a positive HIV (ELISA and Western blot) test result;

12. A positive Hepatitis B surface antigen (HBsAg) test result;

13. Any surgical or medical condition which might significantly alter the absorption, distribution or excretion of any drug. The Investigator should be guided by evidence of any of the following:

1. History of clinically significant inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;

2. History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;

3. History of pancreatic injury or pancreatitis;

4. History or presence of liver disease or liver injury as indicated by lab values such as SGOT, SGPT, GGT, alkaline phosphatase, or serum bilirubin 1.5 times greater than the upper limit of normal;

14. Clinically significant ECG abnormalities or vital sign abnormalities at screening or a history of unstable, severe, or clinically significant cardiovascular disease (e.g., myocardial infarction within previous 6 months, unstable angina, cardiac failure, second/third degree atrioventricular block);

15. Subjects taking any unapproved prescription or over-the-counter medications; all concomitant medications must be discussed with and approved by the sponsor prior to enrollment;

16. A known hypersensitivity to tasimelteon or drugs similar to tasimelteon including melatonin;

17. Pregnant or lactating females;

18. Inability to swallow the study medication whole;

19. Any other sound medical reason as determined by the clinical Investigator.

Groups 1 - 2 (renal impairment)

1. Subjects with clinically significant abnormal findings, not consistent with clinical disease, upon physical examination, ECG, or laboratory evaluation;

2. Evidence of progressive renal disease within 4 weeks prior to screening;

3. Acute renal failure or nephrotic syndrome;

4. Current hematuria of urologic origin;

5. Any significant change in chronic treatment medication as determined by the clinical Investigator.

Group 3 (healthy matched controls)

1. Use of unapproved prescription medication within 1 month of dosing and OTC medication within 14 days prior to dosing;

2. History or presence of impaired renal function as indicated by abnormal (>ULN) creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria).

3. A positive hepatitis C test result.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
Tasimelteon
20mg capsule, once
Tasimelteon
20mg, once

Locations

Country Name City State
United States Clinical Pharmacology of Miami, Inc. Miami Florida
United States DaVita Clinical Research Minneapolis Minnesota
United States Orlando Clinical Research Center Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
Vanda Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tasimelteon pharmacokinetic parameters (AUC, Cmax, Tmax) Predose, 0.25, 1, 1.5, 2, 4, 6, 8, 12, 24, 30, and 36 hours post-dose No
Secondary Pharmacokinetic parameters (AUC, Cmax, Tmax) of tasimelteon metabolites M3, M9, M11, M12, M13, and M14 Predose, 0.25, 1, 1.5, 2, 4, 6, 8, 12, 24, 30, and 36 hours post-dose No
Secondary The percentage of tasimelteon and its metabolites that are removed by hemodialysis (AUC) paired arterial and venous samples 4, 6, 8 hours after dosing No
Secondary The ratio of plasma protein bound versus unbound fractions of tasimelteon and metabolites M9, M11, M12, M13, and M14 0.5 and 3 hours post dose No
Secondary Safety and tolerability as measured by spontaneous reporting of AEs, and clinically significant changes in laboratory parameters, ECG parameters, and vital signs 36 hours Yes
Secondary The Columbia-Suicide Severity Rating Scale will be used to assess suicidal behavior and ideation. once per day at Screening (approximately day -7), Day -1 (baseline), Day 2 (end of study) Yes
See also
  Status Clinical Trial Phase
Completed NCT01937975 - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Phase 1
Completed NCT03284164 - Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex Phase 1
Completed NCT05992155 - A Study of TAK-279 in Adults With or Without Kidney Problems Phase 1
Completed NCT05004311 - The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Phase 1
Completed NCT04963738 - A Study of JNJ-73763989 in Adult Participants With Renal Impairment Phase 1
Terminated NCT02508740 - Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Phase 1
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Terminated NCT00984113 - Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00750620 - A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment Phase 1
Completed NCT00842868 - The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases N/A
Completed NCT00499187 - Fanconi Syndrome Due to ARVs in HIV-Infected Persons Phase 4
Completed NCT01331941 - A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function Phase 1
Completed NCT05489614 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment Phase 1
Completed NCT03259087 - Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005) Phase 1
Completed NCT05086107 - Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment Phase 1
Recruiting NCT05349851 - Bowel Cleansing With Renal Impairment
Completed NCT03660241 - A Renal Impairment Study for PF-04965842 Phase 1
Recruiting NCT06037031 - A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function Phase 1
Completed NCT03289208 - Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment Phase 1
Completed NCT02942810 - To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment Phase 1